CLX

Business Profile & Competitive Position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, generating fiscal 2026 net sales of $6.7 billion with about 9,200 employees in roughly 25 countries and sales in about 95 markets. Its consumer-facing portfolio includes Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while the professional side sells under the Purell, CloroxPro, and Clorox Healthcare brands.

Competitive position is best judged from the actual returns figures. The net margin is 8.7%, which is a moderate, mid-tier level for branded consumer staples—it suggests pricing power and cost discipline, but not an unusually wide moat. The reported ROE of -1,893.5%, however, is not a meaningful operational return metric here. A figure that extreme usually reflects a negative or very small shareholders’ equity base (for example, from accumulated deficits, substantial buybacks, or accounting adjustments) rather than an operating loss. Because of that distortion, investors typically look at profitability through the net margin and cash-flow profile rather than ROE. The low beta of 0.54 confirms the stock behaves more defensively than the overall market, consistent with everyday household demand.

Financial Posture

Clorox currently carries a market capitalization of $13.0 billion and trades at a P/E ratio of 22.3. That multiple sits at a modest premium to many slower-growth staples names, implying the market still assigns some value to its brand portfolio and the GOJO integration, while also pricing in the recent profit pressure.

Profitability remains anchored by the 8.7% net margin. Again, the headline -1,893.5% ROE is not telling the same story as the income statement; it is a balance-sheet artifact. The beta of 0.54 underscores that the equity tends to move only about half as much as the broader market, which is characteristic of a defensive consumer name. Overall, the financial posture is one of a stable, branded household-products company with average profitability metrics and low market sensitivity, carrying the accounting complexity of a deeply negative equity denominator.

Strategic Priorities & Outlook

Clorox’s most recent 10-K outlines several near-term priorities under its IGNITE strategy. The plan is built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio.

Operationally, management is focused on completing and optimizing a new enterprise resource planning (ERP) system and broader digital transformation to drive long-term efficiencies in supply chain, digital commerce, innovation, and brand building. A major recent move was the April 2026 completion of the GOJO Industries acquisition, which expands the health and hygiene portfolio and strengthens the business-to-business presence. Integrating GOJO and growing professional and institutional markets is identified as a key priority. The company also plans to invest in strong brands, strategic digital capabilities, and a streamlined operating model to build a more resilient business.

The filing also flags that fiscal 2026 organic sales and earnings declined, with diluted EPS down 26%, partly due to macroeconomic headwinds and ERP transition timing that had pulled some sales into fiscal 2025. Customer concentration is notable: Walmart accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half of consolidated net sales. Additionally, the Glad bags and wraps venture with P&G expired on January 31, 2026; Clorox purchased P&G’s 20% interest, and Glad retained core intellectual property licenses on a royalty-free basis.

Macro & Geopolitical Exposure

As a Consumer Defensive / Household & Personal Products company, Clorox is exposed to a familiar set of macro and industry-level factors. Demand for cleaning, bags, cat litter, charcoal, and personal-care items is relatively recession-resistant, but input costs—resins, chemicals, packaging materials, and energy—can move with commodity markets and affect margins. Currency risk is real because roughly 25 countries and 95 markets generate international revenue, so a stronger U.S. dollar can compress reported results.

Regulatory exposure includes consumer-product safety rules, environmental and disinfectant registrations (such as EPA oversight in the U.S.), and advertising/labeling standards. Trade policy matters because raw materials and packaging may cross borders, while tariffs or supply-chain disruptions can raise costs or limit availability. Retail concentration—Walmart alone at 26% and the top five at about half of sales—also gives large distributors significant bargaining leverage, which can pressure pricing and promotional spending.

Recent Developments

Recent headlines have centered on institutional positioning and the GOJO integration. On August 24, 2026, defenseworld.net reported that Barrow Hanley Mewhinney & Strauss LLC acquired 106,377 shares of Clorox. The same day, defenseworld.net also noted that Bank of New York Mellon Corp made a new $123.15 million investment in the company. Earlier, on August 22, 2026, defenseworld.net reported that BlackRock Inc. acquired 10,044,423 shares. On August 21, 2026, zacks.com published “How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook,” reflecting ongoing analyst focus on the acquisition’s contribution.

At the current snapshot, CLX was trading at $107.685 with an RSI of 62.1 and a 50-day EMA of $100.98. The price sits above the 50-day moving average, and the RSI is near neutral-to-warm territory without being deeply overbought.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Clorox has beaten consensus 6 out of 8 times, for a 75% beat rate. The average earnings surprise across those quarters is 9.4%, and the average 5-day price move after earnings is +1.67%, classified as an upward drift. That combination—a high beat rate, meaningful average surprise, and positive post-earnings drift—shows that the stock has generally rewarded positive earnings outcomes, though the reaction is not uniform.

The four most recent quarters illustrate that variability. On August 3, 2026, Clorox reported EPS of $1.66 against an estimate of $1.64, a 1.2% surprise and a beat, and the stock rose 6.52% the next day and 9.61% over the following five days. On April 30, 2026, a beat of $1.64 vs. $1.55 (a 5.8% surprise) was met with a -9.67% next-day drop and a -4.49% five-day decline, suggesting the market had embedded a stronger outlook or was reacting to guidance. On February 3, 2026, the company missed with $1.39 vs. $1.43 (-2.8% surprise), yet the stock rose 2.43% the next day and 5.63% over five days, showing that price action does not always follow the headline beat/miss. Finally, on November 3, 2025, a $0.85 vs. $0.818 beat (3.9% surprise) produced a 1.17% next-day gain but a -4.08% five-day move.

The next reporting date is scheduled for November 3, 2026 (After Close), with a consensus EPS estimate of $1.11.

For a deeper dive into how institutional analysts are weighing the GOJO integration, margin recovery, and the upcoming November 2026 earnings report, explore the full institutional verdict on Clorox.